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Immunology of the Acquired Immunodeficiency Syndrome 
Patrick W. McLaughlin, MD* and Carl B. Lauter, MD** 
The Acquired Immunodeficiency Syndrome (AIDS) first 
recognized in 1981, has been extensively studied, and 
the most recent studies have demonstrated that its 
defects extend well beyond the apparent deficient 
cell-mediated immunity to include humoral immunity, 
autoimmunity, and abnormal immunoregulation. The 
recent discovery ofa retrovirus, HTLV III, as a possible 
etiologic agent is discussed in relation to other viruses 
known to cause immunodeficiency. Simian AIDS, an 
animal model of virus-induced immunodeficiency, is 
also discussed. Recommendations are made regarding 
the interpretation and limitations of immune testing in 
AIDS, includinga discussion of how apparently healthy 
homosexuals and groups at risk develop an immu-
nologic profile which mimics that of patients with AIDS. 
J\r\ce late 1981, an unexpected outbreak of oppor-
tunistic infections and unusual neoplasms has been 
noted, described, and studied (1-4). This outbreak ap-
pears to have had its onset in the United States in 
1978-1979. The affected patients lacked the usual con-
genital or acquired immunosuppressive background 
illnesses that would be expected to predispose to such 
infections as Pneumocystis pneumonia and such neo-
plasms as disseminated aggressive Kaposi's sarcoma. 
The term "acqu i red immunodef ic iency syndrome" 
(AIDS) is partially inaccurate, since it does not really 
differentiate the current syndrome from many known 
acquired immunodeficiency states such as leukemia, 
lymphoma, systemic lupus erythematosus, and mal-
nu t r i t i on . In add i t i on , exogenous factors such as 
t reatment w i th cor t icostero ids and other immune 
suppressing medications can cause acquired immu-
nodeficiency. Perhaps a more descriptive (albeit, more 
cumbersome) term could be the " id iopath ic" acquired 
immunodeficiency syndrome. This report wi l l attempt 
to summarize and review the immunologic abnormali-
ties that have been described in AIDS and its apparently 
related disorders. We wi l l also review such immu-
nologic data as are available in normal healthy controls 
and high-r isk groups, eg, homosexual men , intra-
venous drug users, and hemophil ia patients. 
General Overview of the Immune System 
The immune system is complicated, and concepts of 
its ongins, funct ions, controls, and derangements are 
continuously changing. Newer tools, such as hybrid-
oma-produced monoclonal antibodies to cell surface 
markers on lymphocytes and other effector cells have 
provided more informat ion, yet raised more questions. 
The simplif ied out l ine of the immune system which 
fol lows wil l serve as a ground for the discussion that 
fol lows. 
The immune system has "survei l lance" functions to 
protect humans (and other vertebrates) f rom infections 
and cancer. Mult ipotent ial stem cells arise during em-
bryogenesis and develop further into two major popu-
lations of lymphoid stem cells (5-8). One of these, pre-T 
cells, leaves the bone marrow, enters the epithelial 
thymus, and matures there into mature T-cells under 
the influence of local thymic hormones. Mature T-cells 
leave the thymus and populate the paracortical and 
medullary areas of lymph nodes, the central regions of 
the periarterial lymphoid sheaths of the spleen, and 
other sites. T-cells recognize foreign antigens and self 
because of receptors on their surfaces. This system is 
genetically control led. A variety of T-cell surface anti-
gens can be identified using monoclonal antibodies, and 
these antibodies can define T-cell subpopulations (5). 
B-cells mature in the bone marrow of mammals. The 
cell membrane of these cells incorporates IgD and IgM, 
and these serve as recognit ion units for antigen(s). 
After specific antigenic st imulat ion, B-celis, usually 
under the influence of helper T-cells, undergo blastic 
transformation, proliferate, and differentiate further. 
Diversification occurs, and the five classes of immu-
noglobulins are produced and secreted. The B-cells 
mature further into plasma cells which secrete either 
IgG, IgM, IgA, IgD, or IgE in varying quantities. 
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T-cells recognize antigen(s) and a self marker, la, coded 
by the HLA-D region in the major histocompatibil i ty 
system. This encounter results in the blastic transfor-
mation and pro l i fe ra t ion of specif ic T-cell clones. 
However, in contrast to the change described for the 
B-cells, several T-cell subpopulat ions have specific 
funct ions, eg, memory, suppressor activity, helper 
activity, cytotoxicity, and lymphokine product ion. A 
number of lymphokines (soluble mediators or hor-
mones released by lymphocytes that influence other 
immune cells) have been ident i f ied, including inter-
ferons, migration inhibi t ing factor (MIF), and transfer 
factor. 
Monocyte-macrophages are involved in these pro-
cesses in at least two steps (7). Early on , these cells 
encounter new antigens, "process" them, and present 
them to wandering T- and B-cells. Once "act ivated" by 
these antigens, the T- and B-cells undergo the changes 
described earlier. Eventually, the lymphokines (eg, MIF 
and others) released by these activated lymphocytes 
further influence the monocyte-macrophages to per-
form their effector functions in a more vigorous manner 
(turned on , "angry, " activated macrophages). One such 
specialized cell in the epidermis, the Langerhans cell , 
serves as the antigen-presenting cell in the skin. Other 
types of these cells are found in important areas in the 
lymphoid tissues and organs. 
A review of the immune system organization requires 
more detailed ment ion of the chemical signals that 
regulate cell growth and dif ferentiat ion (8). A major 
lymphokine is interleukin-2, which was originally de 
scribed in the mid-1970s and named T-cell growth factor. 
Interleukin-2 is produced by T-cells, and it in turn stimu-
lates the division of T-cells. In addi t ion, interleukin-2 
stimulates T-cells to produce gamma (immune) inter-
feron which also serves as a lymphokine wi th several 
defined important funct ions. Interleukin-2 seems to 
have a l imited range of sources and targets. Only T-cells 
that are ant igen ica l ly s t imu la ted w i l l respond to 
interleukin-2. In contrast, interleukin-1 has a wide range 
of effects on non-lymphocytic cells which contr ibute to 
inf lammation. Evidence has accumulated to suggest 
that interleukin-1 and endogenous pyrogen are the 
same molecule! 
The sequence of events can be oversimpl i f ied and 
summarized as fo l lows: macrophages release inter-
leukin-1, which stimulates the product ion of interleu-
kin-2 by T-cells that have been activated by antigen. 
Receptor-bearing T-cells are stimulated to divide by 
interleukin-2. Gamma interferon is produced, and it 
then enhances the cytotoxic activities of T-lymphocytes, 
macrophages, and natural killer (NK) cells. Immune 
interferon also amplifies the response of macrophages 
to specific antigens by increasing the expression on 
their surface of certain class II histocompatibil i ty mol-
ecules that are needed for the presentation of foreign 
antigens. 
B-cell activation cell division requires B-cell growth 
factor which is produced by T-cells and inter leukin-1. 
Addit ional lymphokines, called B-cell di f ferent iat ion 
factors, are then needed to stimulate the B-cells to a 
state where they can produce antibodies. 
In the peripheral b lood, approximately two thirds o f the 
circulating lymphocytes are T-cells, and one third are 
B-cells. Of the T-lymphocytes in the b lood, approxi-
mately two thirds are helper T-cells and one th i rd 
suppressor T-cells, giv ing the " n o r m a l " he lper- to-
suppressor ratio of approximately 1.2:2.2 in normal, 
healthy adults (5). In other tissues, T-cells constitute 
more than 75% of the lymphocytes in lymph and lymph 
nodes, and B-cells more than 75% of the lymphocytes in 
the b o n e m a r r o w . The p r o p o r t i o n of T- and B-
lymphocytes in the spleen is approximately 50% of 
each. 
Immunologic Findings in AIDS 
with Routine Screening Techniques 
In view of the complexity of the immune system, the 
many tests available for use or abuse, and the need for 
accurate, t imely, and cost-effective diagnostic tests in 
patients at risk for AIDS, it is very important for cl ini-
cians to be aware of the office and laboratory clues that 
can be readily obtained wi thout a sophisticated immu-
nology laboratory. It should be reemphasized that AIDS 
is a syndrome; even wi th the most expensive tech-
nology available today, the diagnosis cannot be made 
with laboratory testing alone. 
Patients who meet the rigorous Centers for Disease 
Control (CDC) criteria (2,3) for the diagnosis of AIDS 
wil l almost invariably have evidence of cellular immu-
nodef ic iency. Oppor tun is t i c infect ions w i th micro-
organisms (especially viral, fungal, mycobacterial, and 
parasitic) and/or the presence of certain tumors against 
which cellular immunity (T-cell mediated immunity) is 
considered most vital remain the essential components 
in the diagnosis of AIDS. In these patients, and in 
several groups that have been identi f ied as being at 
increased risk, immunologic testing is indicated. 
The m in imum evaluat ion that should be done on 
patients at risk for AIDS would include (see Table I): 
complete history and physical examination, complete 
blood cell count wi th differential whi te blood cell and 
platelet count, erythrocyte sedimentation rate, liver 
f unc t i on tests, sero log ic test fo r syphi l is , mono-
nucleosis spot test, hepatitis A and B markers, immu-
noglobul in quanti tat ion, delayed hypersensitivity skin 
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TABLE I 
Evaluation of the Patient at Risk for AIDS: 
Screening with Routine Office Procedures 
1. Complete history and physical examination 
2. Complete blood count with differential count: peripheral blood 
a) Total absolute lymphocyte count 
b) Peripheral blood morphology 
c) Platelet count 
3. Liver-related tests 
a) Liver enzymes, bilirubin 
b) Hepatitis viral markers 
1. IgG and IgM-specific hepatitis A antibodies 
2. Hepatitis B surface antigen, surface antibody, and core 
antibody 
4. Venereal diseases-related tests 
a) Complete genital examination 
b) VDRL 
5. Mononucleosis-related tests 
a) Monospot test 
b) Save sera for EB virus and CMV titers 
6. Autoimmune-related tests 
a) ANA 
b) Coombs' 
c) Urinanalysis (for nephritis) 
7. General immunologic testing 
a) Immunoglobulins: quantitation of IgG, IgM, and IgA levels 
b) Delayed hypersensitivity skin tests with at least 3 antigens, 
eg, Candida, mumps, trichophyton, and tetanus toxoid 
8. Gastrointestinal tract-related testing 
a) Stool specimens for ova and parasites 
b) Stool specimens for routine C & S 
c) Stool specimens (with throat and rectal) for gonorrhea 
d) Stool for occult blood 
e) Proctosigmoidoscopy if any Gl symptoms or history of anal 
receptive intercourse 
9. Chest X-ray 
tests, and chest x-ray. In patients with gastrointestinal 
complaints, especially in homosexual men, an exten-
sive search should be made for infectious agents in 
stool specimens. Abnormalit ies of the skin should be 
evaluated by a dermatologist, and biopsies should be 
performed on any suspicious lesions. Persistent, unex-
plained, enlarged lymph nodes should also be biopsied 
to rule out lymphoma, Kaposi's sarcoma, and infect ion, 
and also for prognostic purposes (9). 
Recently, Kalish, et al (10) reported that leukopenia was 
found in 45% of 11 patients wi th AIDS, 23% of 39 patients 
with the AIDS-associated lymphadenopathy syndrome 
(LAS), 9% of 32 mildly symptomatic homosexual men, 
4% of 57 asymptomatic homosexual men, and none in 
39 asymptomatic heterosexual controls. Similar inci-
dences of anemia and thrombocytopenia were reported 
in the same series. Cutaneous anergy was identif ied in 
88% of 8 patients wi th AIDS, 62% of 39 patients wi th LAS, 
37% of 27 mildly symptomatic homosexual men, 18% of 
60 asymptomatic homosexual men, and 23% of con-
trols. Elevated levels of IgG, IgA, and IgM were found in 
56% of 9, 67% of 9, and 22% of 9 patients wi th AIDS, 
respectively. Elevated immunog lobu l i n levels were 
found less often in the LAS patients and infrequently in 
the other groups. Elevated levels of IgM were found , 
however, in 37% of 30 mildly symptomatic homosexual 
men, 24% of 59 asymptomatic homosexuals, and 1 1 % of 
37 contro ls . Mean values for the total lymphocyte 
counts were significantly dif ferent among five study 
groups already described; the mean number of cells 
was lowest for the AIDS patients and was stepwise 
increased in the LAS patients, the mildly symptomatic 
male homosexuals, and the asymptomatic homosexual 
men. 
The values of these routine laboratory tests have been 
similarly altered in AIDS patients who were not male 
homosexuals, eg, intravenous drug abusers, hemo-
phi l ia patients, and sexual contacts and infants in 
households of AIDS patients (1,4). Generally, these 
patients have high incidences of titers to hepatitis A, 
hepatitis B, cytomegalovirus (CMV), and Epstein-Barr 
virus (EB virus). 
T-cel l Changes in A I D S , Patients at Risk 
for A I D S , and Related Disorders 
The T-cell changes in AIDS include changes in number 
(lymphopenia), type (suppressor-helper), and funct ion 
(decreased response to antigen and mitogen). The most 
publicized and familiar change is the decreased helper/ 
suppressor ratio. Normally approximated, 64% of T-
cells are helper, and 36% are suppressor. The normal 
ratio, therefore, is 1.5-2:1. This ratio provides a useful 
index of immunologic stance, but it can be deceptive if 
taken alone. Recent studies (10,11) reveal that absolute 
changes in T-helper cells and T-suppressor cells are 
more important than changes in the ratio. 
In AIDS, for example, the dominant change is in the 
T-helper cells. Suppressor T-cells are often normal or 
increased, and there is a profound drop in the ratio as 
well (usually =s 0.5 in patients wi th opportunist ic infec-
t ion) . In healthy homosexual men , the ratio is de-
creased but to a lesser degree; in most cases the 
decrease is due toan increase in T-suppressor cells. This 
same pattern is noted in healthy hemophiliacs on Factor 
V l l l replacement therapy. In these two situations, T-
helper cells may be normal or increased. The LAS is a 
mixed group. In 30% there is a definite decrease in 
T-helper cells, and in 20% an increase in T-suppressors. 
The combinat ion, therefore, of the profound absolute 
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decrease in T-helper cells wi th an associated decrease in 
ratio is relatively specif icfor AIDS but does occur in 30% 
of patients wi th LAS. Even given this combinat ion, it is 
not possible to make the diagnosis of AIDS with these 
laboratory tests alone. 
Changes similar to those seen in patients wi th AIDS 
(decreased T-helper cells wi th decreased ratio) are seen 
in patients dur ing the acute phase of several viral, my-
cobacterial, and fungal infections (12). This is usually a 
transient phenomenon , however, and T-suppressor 
cells are often markedly increased. The T-helper cell 
depletion resolves quickly, but the T-suppressor cell 
increase may persist for months. Because cytomegalo-
virus (CMV) infection is common in the groups at risk 
for AIDS and is known to decrease the T-helper/T-
suppressor cell ratio, it was suspected earlier to be the 
etiologic agent in AIDS (13). It is more probable that 
CMV is an opportunist that potentiates rather than 
initiates the immunosuppression. The AIDS patient is 
unable to clear the CMV infection and remains in an 
"acute phase" wi th prolonged decrease in T-helper 
cells and ratio. 
Al though the changes in T-cell subsets are strongly 
emphasized in the l i terature, the more impor tan t 
change in AIDS is loss of function (14). Thus, not only are 
there fewer cells, but the remaining cells fail to respond 
in normal fashion to foreign antigens or mitogens. Skin 
tests for delayed hypersensitivity are weak or negative, 
and the T-cells fail to respond when they are stimulated 
in vitro with mitogen. Several attempts have been made 
to define and reverse the T-cell defect, but the first and 
most basic question is whether this is reversible at all. 
Addit ion of interleukin-2 has been shown to improve 
lymphocyte responses in v i t ro, but in vivo studies are 
still in progress. Again, studies of viral infections reveal 
that similar functional defects occur. Lymphocytes were 
taken from patients infected wi th CMV and immediately 
stimulated with mitogen but failed to respond. When 
the same lymphocytes were cultured for seven days and 
restimulated, they responded appropriately (13). This 
reaction suggests that in CMV infections, at least, the 
defect is probably not in the T-cell itself but is mediated 
by suppressor substances that the T-cell can shed. One 
hope is that AIDS patients may either block the sup-
pressor substance(s) or provide enough activator to 
overcome the defect. 
As stated above, CMV probably potentiates but does 
not initiate the changes in T-cell number and funct ion. 
As in renal transplant patients, CMV can act only against 
a background of immunosuppression. What, then, is 
the infect ious agent "equ i va len t " of cyclosporin-A 
which initiates the AIDS process? Recently, a virus re-
lated to the human T-leukemia/lymphoma virus (HTLV) 
has been isolated f rom a number of AIDS patients 
(15,16). This virus is known to preferentially attack T-
helper cells, but instead of leading to the neoplastic 
proliferation seen in T-cell leukemias and lymphomas 
due to HTLV-I and I I , this new virus, HTLV-III, appearsto 
destroy the T-helper cells, init iating the profound and 
sustained immunosuppressant characteristics of AIDS. 
For this reason, it has been proposed that HTLV stands 
fo r human T-cel l l y m p h o t r o p i c v i rus ins tead of 
leukemia/lymphoma virus. 
B-cell Changes in AIDS 
Unti l 1983, most references on AIDS reported that 
humoral immuni ty was intact. This conclusion was 
based on the fact that immunoglobul in levels are nor-
mal or increased in patients with AIDS and that such 
patients are plagued more by l ife-threatening infections 
usually control led by cell-mediated immuni ty rather 
than by humoral immunity. The findings of Lane, et al 
(17) and Ammann, et al (18) were somewhat surprising, 
for they reported severe B-cell dysfunction in AIDS 
patients. In spite of decreased T-helper cells, the AIDS 
patients had hyperactive B-cells, wi th fewer B-cells in 
the resting state and many more B-cells spontaneously 
secreting immunog lobu l i n . However , these B-cells 
failed to produce adequate antibody response to speci-
fic new and recall foreign antigens, even those not 
requir ing T-helper cell funct ion. Thus, the B-cells were 
" tu rned o n " in one sense but unresponsive in another. 
The mechanism of this B-cell defect is not known at 
present, but a viral infect ion, EB virus mononucleosis, 
may provide a model of what may be happening in AIDS 
patients. In fact, EB virus reactivation may even be the 
cause of the B-cell defect in AIDS. Lane, et al (17) were 
able to culture EB virus f rom every patient displaying the 
B-cell changes. B-cells have a receptor for EB virus: The 
virus acts as a mitogen, directly stimulating the B-cell to 
mature, proliferate, and secrete immunoglobul in (19). 
As part of the host response to this B-cell prol i ferat ion, 
T-suppressor and cytotoxic cells increase markedly. The 
atypical lymphocytes seen in infectious mononucleosis 
are largely T-suppressor and cytotoxic cells. 
In summary, in AIDS the unchecked EB virus or other 
viruses may drive the B-Iymphocytes to secrete immu-
noglobul in, but this is a nonspecific, generalized re-
sponse, and the ability to respond to other specific 
foreign antigens is severely impaired. 
The Lymphadenopathy Syndrome 
The immunologic aspects of the LAS represent the ful l 
spectrum of the T- and B-cell changes discussed above. 
Histologically, there are two extremes (9). The majority 
of lymph node biopsies reveal fol l icular hyperplasia. 
The foll icle is the node area usually occupied by B-
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lymphocytes. This pattern is identical to the pattern 
seen in early mononucleosis when B-cells are driven to 
proliferate by the EB virus infect ion. At the other ex-
treme, the follicles atrophy and are surrounded by a 
hyper t roph ied parafol l icular area composed of T-
suppressor cells, which presumably have halted the 
B-cell overgrowth. This pattern is similar to the pattern 
in resolving mononucleosis. Some homosexuals wi th 
the LAS do not have a mild or prodromal fo rm of AIDS, 
but rather seem to have a prolonged mononucleosis-
like illness which may be due to EB virus or CMV. To 
date, between 1-25% of LAS patients wi l l develop frank 
AIDS. The histologic type most associated wi th pro-
gression to AIDS is the foll icular atrophy type. It has 
been suggested that in their attempt to shut down the 
B-cell prol i ferat ion, the T-suppressor and T-cytotoxic 
cells are finally victorious, but the victory is pyrrhic. The 
massive outpour ing of T-suppressor cells contributes 
further to the already intense immunosuppression of 
AIDS. Supporting the view that the lymph node rep-
resents a kind of summation of T- and B-changes is the 
significant reduction of T-helper cells in the lymph 
nodes of patients wi th LAS and Kaposi's sarcoma (20). 
Malignancy and AIDS 
The same immunosuppression which allows opportunis-
tic infections may allow the emergence of malignancy in 
patients with AIDS. The most common malignant tumor 
in AIDS is Kaposi's sarcoma, a tumor of endothelial cell 
or igin. The same aggressive form of Kaposi's sarcoma is 
seen in renal transplant patients. Perhaps the most 
interesting aspect of Kaposi's sarcoma in the setting of 
renal transplant recipients is the complete remission 
that can be seen after wi thdrawal of immunosup-
pression. Unfortunately, the immunosuppression can-
not be conveniently decreased in AIDS, and meaningful 
remissions have not been recorded. 
CMV and EB virus may piay a central role in the patho-
genesis of the common malignant tumors seen in AIDS 
patients. DNA from CMV has been identif ied in biopsy 
specimens of Kaposi's sarcoma (21). Several theories 
have been proposed to explain the relationship. CMV 
infects many cells and may directly cause proliferation 
of endothelial cells, or it may infect and convert a 
"reactive prol i ferat ion" into a neoplastic one, wi th the 
CMV acting as an oncogene. 
The B-cell lymphomas seen in patients wi th AIDS are 
probably related to EB virus (22). As discussed above, EB 
virus drives B-cells to polyclonal prol i ferat ion, and a 
malignant clone may emerge f rom this stimulated pool 
(23). Whether or not the virus is responsible for this 
t ransformat ion to malignancy is not clear, but un-
doubtedly the initial proliferation is driven by a virus. 
Burkitt's lymphoma, another EB virus-related tumor, 
has also been seen in AIDS patients. 
Autoimmune Manifestations 
of AIDS 
Similarities between AIDS and autoimmune disorders 
(Table II) have been noted in several reports (1,4). 
Among these are the general suppression of cellular 
immune reactions, polyclonal hyperglobulinemia, and 
an immune thrombocytopenia (24). Less of ten, positive 
tests for antinuclear antibodies and a Coombs-positive 
hemolytic anemia have been described. As noted ear-
lier, leukopenia is common, and abnormalities of T-cell 
subsets are almost universally found. 
TABLE II 
Autoimmune-like Changes and AIDS 
1, Suppression of cellular immunity 
2, Polyclonal hyperglobulinemia 
3, Immune thrombocytopenia 
4, Antinuclear antibodies 
5, Coombs' positivity (and hemolytic anemia) 
6, Leukopenia 
7, Circulating levels of acid-labile alpha interferon 
8, Elevated blood levels of circulating immune complexes 
9, Circulatory lymphocytotoxic antibodies 
10. Systemic lupus erythematosus-like circulating anticoagulant 
11. Elevated blood levels of beta-2 microglobulin 
12. Immune complex nephritis and nephrotic syndrome 
One part icular ly interest ing f i nd ing , conf i rmed by 
several laboratories, is the high incidence of elevated 
circulating levels of a peculiar acid-labile form of human 
alpha (leukocyte) interferon (25). In the initial report, 
0/22 normal controls had this abnormality, whi le 2/25 
asymptomatic male homosexuals had small amounts 
(4-8 lU/ml) in their b lood. In contrast, 10/35 patients wi th 
the LAS and 17/27 wi th Kaposi's sarcoma had between 4 
and 60 lU/ml in their circulation. The only other medical 
condit ion known to date in which the blood has a high 
incidence and large quantities of this acid-labile alpha 
interferon is systemic lupus erythematosus. 
Other abnormalities in AIDS and LAS patients which 
suggest " o v e r l a p " or c o m m o n or ig ins w i th auto-
immune diseases include positive tests for circulating 
i m m u n e comp lexes , an SLE-like c i rcu la t ing ant i -
coagulant, lymphocytotoxic antibodies, and elevated 
levels (1-4) of beta-2-microglobulin levels (26). The latter 
represents the light chain moiety of class I HLA-antigens 
on cel l surface membranes. Increased beta-2-mi-
croglobulin levels may be found in several lymphopro-
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liferative disorders and autoimmune diseases including 
infectious mononucleosis, Crohn's disease, rheuma-
to id ar thr i t is , Sjogrens synd rome , systemic lupus 
erythematosus, acute and chronic hepatitis, primary 
biliary cirrhosis, and sarcoidosis. 
A recent report described the nephrotic syndrome in 
9/92 patients with AIDS (27). Two other patients in that 
series had azotemia and proteinuria of less than 3.5 
grams in 24 hours. Five of these 11 patients were intra-
venous drug addicts, and nine patients ( including six 
non-addicts) developed rapidly progressive uremia. 
Pathologic examination showed focal and segmental 
glomerulosclerosis. Immunologic staining of the renal 
tissue usually showed intraglomerular deposits of IgM 
and C3, suggestive of an immune complex nephrit is. 
Lastly, an inordinate and unexpectedly high incidence 
of adverse and/or allergic reactions has been noted in 
patients who had AIDS and were treated wi th t r imeth-
oprim-sulfamethoxazole. In one series (28), only 5/37 
patients who were started on this drug were able to 
complete the therapy. Therapy had to be discontinued 
for the others because of fever, rash neutropenia, trans-
aminase elevation, azotemia, and hypoglycemia. An 
analogy between this problem and the high incidence 
of ampici l l in-induced rashes in patients wi th infectious 
mononucleosis has been suggested (29). 
The significance of the autoimmune-l ike abnormalit ies 
in patients wi th AIDS and the AIDS-associated LAS is 
unknown. Ongoing active infection is known to trigger 
autoimmune types of changes, and these patients cer-
tainly are persistently and often heavily infected wi th a 
variety of viral and other organisms. Whether these 
changes represent merely a secondary effect of such 
uncontrol led (eg, viral) infection or indicate a more 
basic i m m u n o l o g i c a b n o r m a l i t y r e m a i n s to be 
determined. 
Miscellaneous Other Immunologic 
Changes and AIDS 
In add i t ion to the several al terat ions in immun i ty 
already described, a variety o fo ther abnormalit ies have 
been noted (Table III). Almost all reports on AIDS o r t he 
LAS have described normal to increased numbers of NK 
cells but decreased NK cell activity (30). NK cells were 
first described about ten years ago as cells that are 
capable of an immediate cytotoxic (killer) response to 
tumor cells (31). It is probable that NK cells and macro-
phages do, in fact, represent the first l ine defense 
against cancer. Current information suggests that NK 
cells also may eliminate microbial agents by ki l l ing 
virus-infected host cells, parasites, fungi , and bacteria, 
and may contr ibute to graft-vs-host disease and/or 
autoimmunity. 
TABLE III 
Immunologic Changes in AIDS: Overview 
1. Office (screening) tests 
a) Absent or diminished delayed hypersensitivity on skin testing 
b) Hyperglobulinemia 
c) Lymphopenia 
2. Office (more advanced) tests 
a) Decreased T-helper cell: T-suppressor cell rates («1.2:1) 
b) Decreased absolute number of T-helper lymphocytes 
c) Decreased lymphocyte responses to mitogen stimulation 
d) Normal to increased numbers of NK cells but decreased NK 
cell activity 
3. Autoimmune-like tests (see Table 11) 
4. Miscellaneous other immune tests (generally, research 
laboratory required) 
a) Decreased production of interleukin-1 
b) Decreased production of interleukin-2 
c) Suppressor factors in serum for production of interleukin-2 
d) Altered granulocyte function 
e) Defects in monocyte function 
f) Increased numbers of mast cells in transbronchial tissue and 
lymph nodes 
g) Increased neutrophils and polyclonal B-cell activation in 
bronchoalveolar lavage fluid 
h) Elevated thymosin alpha-1 blood levels 
i) Impaired production of gamma interferon and other 
lymphokines after antigen stimulation of lymphocytes 
j) Polyclonal B-cell activation in blood and inability of these 
cells to respond to new or recall antigens 
k) Decreased number of T-helper cells in lymph nodes 
1) Reduced Langerhans cell numbers in skin 
Other abnormalities in AIDS include decreased pro-
duction of inter leukin-1, decreased product ion of inter-
leukin-2, presence of suppressor factors in serum for 
product ion of interleukin-2 (32), altered granulocyte 
funct ion (33), defects in monocyte chemotaxis and cy-
totoxic activity (34), increased numbers of mast cells in 
transbronchial tissue and lymph nodes (35), increased 
neutrophils and polyclonal B-cell activation in bron-
choalveolar lavage f luid (36) (dichotomy between cir-
culating and regional immunocompetent cells), and 
elevated serum thymosin alpha-1 levels (37). This last 
f inding is interesting because thymosin alpha-1 is one of 
the thymic hormones that inf luences T-cell d i f fer-
entiat ion, including the induct ion of T-helper cells. The 
elevated circulating levels of thymosin alpha-1 could 
represent end organ failure or could result f rom the 
release of hormone f rom thymic epithelial cells under a 
viral attack. The biologic activity of these elevated levels 
also remains to be conf i rmed. 
Impaired product ion of gamma interferon and other 
lymphokines upon exposure to antigens has recently 
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been described in patients with AIDS (14). Gamma inter-
feron stimulates many components of host defenses: 
cytotoxic and NK cell activities, monocyte-macrophage 
activity against intracellular pathogens, lymphocyte 
antiviral activity, antiviral activity of other cells (fibro-
blasts, epithelial cells, etc), expression of HLA-DR (class 
II HLA or la antigens) and F receptors, release of 
inter leukin-1, pr iming for tumoricidal activity, and in-
duction of interleukin-2 receptors. 
Although viral infection of T-helper cells currently rep-
resents the most likely theory for the etiology of AIDS, 
the report of reduced Langerhans cell numbers in the 
skin of AIDS patients is interesting (38). T-cell abnor-
malities can be secondary to generalized B-cell activa-
t ion or defects in the antigen-presenting cell system. It 
is possible, therefore, that the T-helper cell abnormali-
ties are not primary in AIDS and that the Langerhans 
cells (and other dendrit ic cells) might be the target of a 
virus attack; a deficiency in these cells might then result 
in a cascade of secondary T-cell abnormalities. The 
result wou ld be a severe and possibly irreversible im-
munodeficiency state. Gamma interferon and interleu-
kins-1 and -2 can, in v i t ro, correct similar deficiencies in 
Langerhans cells induced by ultraviolet light exposure. 
So far as sexual practices and immune changes are 
concerned, much interest has been generated by the 
f inding of antisperm antibodies in 19/26 homosexual 
men who were anal sperm recipients and smaller per-
centages of antisperm antibodies in sexually active male 
homosexuals who were not anal sperm recipients (39). 
Human seminal plasma has been found to suppress NK 
activity (40,41). The risk of AIDS among male homo-
sexuals appears to be greatest for those who are anal 
sperm recipients and who have the largest number of 
sexual partners (39). 
The use of amyl nitrate has not been shown to correlate 
statistically wi th the development of AIDS in the at-risk 
groups. Although opioids and stress do transiently alter 
T-cell funct ion and lower the T-helper/T-suppressor cell 
ratio (42), there is no evidence that these factors play 
any more than an adjunctive role, if any, in the genesis 
of AIDS. 
Simian AIDS (SAIDS) 
An acquired immunodef ic iency syndrome has been 
noted in monkeys in New England and California (43). 
Endemic immunodeficiency with consistent immunologic 
abnormalities occurred in macaques in the New England 
colony. In California, four separate outbreaks of SAIDS 
have occurred in two species of macaque monkeys. The 
latter illnesses were characterized by malignant lym-
phomas and opportunist ic infections including My-
cobacterium avium-intracellulare. Herpesvirus simiae, 
and progressive mult i focal leukoencephalopathy. In 
other outbreaks, encephalitis, candidiasis, lymphaden-
opathy, splenomegaly, persistent diarrhea, chronic wast-
ing, and cutaneous fibrosarcomas developed. As in 
human AIDS, the outbreaks in primates carried a high 
mortality (44). 
Immunologic testing in SAIDS has revealed varying 
incidences of the f o l l o w i n g : l ymphopen ia , granu-
locytopenia, thrombocytopenia, diminished-to-absent 
delayed hypersensitivity on skin tests, depressed stimu-
lation indices of lymphocytes wi th mitogens, and high 
titers to CMV. SAIDS differs f rom human AIDS in the 
lesser incidence of Pneumocyst is, the hypog lobu-
linemia, and the more normal helper/suppressor T-cell 
ratios that characterize the non-human primate syn-
drome (43,44). Later studies in SAIDS have shown some-
what depressed T-helper/T-suppressor cell ratios. 
A new type D retrovirus has been isolated f rom the 
peripheral blood lymphocytes and pharyngeal secre-
tions of monkeys w i th SAIDS but not f rom healthy 
monkeys using a co-cult ivation technique wi th Raji 
cells, a lymphoblastoid cell line of human origin (45,46). 
Early reports suggest that the type D retrovirus of SAIDS 
does not appear to be closely related to the human T 
lymphoma-leukemia virus (HTLV-III) that is currently 
the leading candidate for the viral etiology of human 
AIDS (15,16). 
Summary and Conclusion 
Much confus ion has occur red because seemingly 
healthy homosexuals may acquire an immunologic pro-
file similar to that of AIDS patients. This can be related to 
the abil i ty of viral infect ions other than the "AIDS 
agent" to cause immunosuppression. In fact, parasitic, 
viral, mycobacterial, and fungal infections are all capa-
ble of causing an immunologic profi le similar to AIDS, 
but the effect is usually transient. In AIDS, the sup-
pression is more severe and more sustained, leading 
finally to a state of immunologic "shock , " a twhich point 
even the most passive, easily control led organisms such 
as Pneumocystis carinii can act as a virulent, deadly 
pathogen. The development of malignancies and auto-
immune changes are also evidence of the profound 
alterations in the immunoregulat ion system of these 
patients. 
The etiologic agent in AIDS may be a new type T-cell 
lymphotropic virus, HTLV-III, which infects and de-
stroys T-helper cells, creating the p ro found immu-
nosuppression characteristic of the syndrome. The 
virus apparently can create the syndrome in people 
outside the recognized risk groups. In homosexual 
men, the immunosuppression presumably induced by 
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this virus is aggravated by infection wi th ubiquitous 
pathogens, such as CMV and EB virus, which cause 
further immunosuppression and the other manifesta-
tions discussed above. 
A similar abnormal immunologic profi le is seen in many 
healthy hemophil iac patients (47), intravenous drug 
abusers (48), and patients who have received mult iple 
transfusions (49). The cause, again, may be repeated 
exposure to common viruses and foreign antigen(s) 
resulting in subclinical immunosuppression. Clearly, 
this does not lead to AIDS as was once suspected, but it 
does lead to an immunologic profi le simlar to AIDS 
which creates confusion and makes it necessary to 
define AIDS clinically rather than by immunologic tests. 
If the accumulating data relating HTLV-III is conf i rmed, 
serologic tests for this virus may simplify the diagnosis 
and, perhaps, lead to the development of a vaccine. 
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